LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Open

SectorGezondheidszorg

67.81 1.95

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

65.78

Max

67.87

Belangrijke statistieken
By Trading Economics
Inkomsten	292M 150M
Verkoop	-75M 377M
K/W Sectorgemiddelde	24.112 50.102
EPS	1.221
Winstmarge	39.832
Werknemers	423
EBITDA	-63M 218M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+29.45% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	501M 8.2B
Vorige openingsprijs	65.86
Vorige sluitingsprijs	67.81

Nieuwssentiment

By Acuity

13%

87%

20 / 344 Rangschikking in Healthcare

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2026, 20:30 UTC

Winsten

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 jun 2026, 23:58 UTC

Marktinformatie

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 jun 2026, 23:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 jun 2026, 23:41 UTC

Marktinformatie

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 jun 2026, 23:01 UTC

Acquisities, Fusies, Overnames

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 jun 2026, 23:01 UTC

Acquisities, Fusies, Overnames

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 jun 2026, 23:00 UTC

Acquisities, Fusies, Overnames

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 jun 2026, 22:57 UTC

Marktinformatie

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 jun 2026, 22:50 UTC

Marktinformatie

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 jun 2026, 21:07 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 jun 2026, 21:07 UTC

Marktinformatie

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 jun 2026, 21:00 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

2 jun 2026, 20:46 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:38 UTC

Winsten

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 jun 2026, 20:21 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:12 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Product Rev $594M

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Loss $177M >PANW

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

29.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 85.8 USD 29.45%

Hoogste 96 USD

Laagste 70 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

20 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.